Study Conduct

Synchrogenix partners with CISCRP on transparency, developing lay language trial summaries for participants

Monday, May 4, 2015

Synchrogenix, a unit of Certara, has partnered with the nonprofit Center for Information and Study of Clinical Research Participation (CISCRP) in an effort to expand lay language summaries for patients who participate in clinical trials. The two will provide more plain language accounts of a clinical trial’s design, objective and findings, also meeting sponsors’ clinical data transparency requirements.

[Read More]

Job satisfaction mixed as workload increases

Friday, May 1, 2015

Since the recession ended six years ago, clinical research professionals have become more optimistic about the economic outlook of their companies. Yet job satisfaction levels are mixed—the workforce has seen its workload and responsibilities rise dramatically, while mean salary levels have increased only slightly when adjusted for inflation.

[Read More]

YourEncore, ACRES partner to drive innovation in clinical research

Wednesday, April 29, 2015

YourEncore, an Indianapolis, Ind.-based company that helps life sciences, consumer products and food sciences companies solve complex development, regulatory and productivity challenges, and the Alliance for Clinical Research Excellence and Safety (ACRES), a Massachusetts-based nonprofit building a global system for conducting clinical research, have partnered to speed innovation in the medical therapy development sector.

[Read More]

TransCelerate BioPharma launches two initiatives to improve clinical research

Thursday, April 16, 2015

TransCelerate BioPharma, a nonprofit organization dedicated to improving the health of people around the world by accelerating and enhancing the R&D of innovative new therapies, has established two new global initiatives which will accelerate and enhance clinical trials. Both initiatives, Placebo/Standard of Care Data Sharing and Electronic Labels for Clinical Trials (e-Labels), aim to create solutions that will have a direct impact on patients, sponsors and investigative sites.

[Read More]